Breathe Well Live Well
|
$100000 cash bail for Worcester man in party-goer's asthma death
Worcester Telegram WORCESTER — A city man was ordered held on $100,000 cash bail Wednesday after pleading not guilty to a manslaughter charge in the death of a Blackstone teen who suffered a severe asthma attack after an altercation last year at a party on Bailey Street. Worcester man pleads not guilty to manslaughter |
View full post on asthma – Google News
|
US Asthma Sufferers Coughing Up More Cash
Newser (Newser) – The New York Times continues its "US health care costs are way higher than the rest of the world" series (see previously here and here) with a look at the most common chronic disease in America: asthma. According to the Times, it's becoming … |
View full post on asthma – Google News
 WA today |
Freeway Bike Hike raises sweat and cash for Asthma Foundation
Perth Now WA's largest cycling community event raised over $190,000 for the Asthma Foundation, which is more than double last year's total. Participants had the option of taking part in several rides including the Full Hike from Mandurah, the Mid Hike from … Freeway awash with yellow to raise money for Asthma Bike hike brings traffic chaos |
View full post on asthma – Google News
 Highland News |
Memorial match cash will help fund vital asthma advice
Highland News CASH raised at a memorial football match is to help teachers and childcarers in Inverness learn how to deal with asthma emergencies. More than £1000 has been donated to an asthma charity after friends of Shaun Scullion, … |
View full post on asthma – Google News
|
SkyePharma Moves To 2010 Pretax Profit, Sees Cash Outflows
Wall Street Journal LN) Wednesday said it swung to a 2010 pretax profit, but it expects substantial cash outflows in 2011 relating to the planned European launch of its flagship asthma treatment Flutiform in the second half of the year. The company also said it expects … |
View full post on asthma – Google News
|
Cost savings boost Vectura's cash resources
Reuters L) said cost savings had put it in a stronger position than expected as it awaits trial results and European approvals for its medicine to treat asthma. The British company, which has developed what is potentially a generic rival to GlaxoSmithKline's … |
View full post on asthma – Google News